| EPB258 | Analysis of the impact of COVID-19 pandemic on PrEP uptake in Toronto: a retrospective 18-month single-site chart review | E-poster | Impact of COVID-19 on HIV care |
| EPB257 | Profile of patients hospitalized with COVID-19 with HIV and AIDS in Mozambique | E-poster | Impact of COVID-19 on HIV care |
| EPB256 | Impact of COVID-19 pandemic on HIV treatment services in 12 PEPFAR-supported sites in 8 provinces, Thailand, 2021 | E-poster | Impact of COVID-19 on HIV care |
| EPB255 | Seroprevalence of SARS-CoV-2 infection and evolution of humoral response in PLWHIV | E-poster | Impact of COVID-19 on HIV care |
| EPB254 | Secondary impacts of the COVID-19 pandemic on Young People Living with HIV in Kenya | E-poster | Impact of COVID-19 on HIV care |
| EPB253 | High levels of Acquired HIV Drug Resistance (ADR) among HIV positive Zambian adults with HIV treatment failure: results from the national ADR survey | E-poster | Resistance to ART |
| EPB252 | Impact of Dolutegravir (DTG) on viral load suppression and HIV Drug Resistance (HIVDR) among Zambian children on ART: Results from the pediatric Acquired HIVDR (pADR) national survey | E-poster | Resistance to ART |
| EPB251 | Virological failure and acquired drug resistance among ART-experienced people living with HIV in Nepal: a nationally representative surveillance study | E-poster | Resistance to ART |
| EPB250 | Profiling integrase mutations after raltegravir salvage therapy failure in Brazil | E-poster | Resistance to ART |
| EPB249 | Combined effects of the K156N integrase polymorphism and 3'PPT resistance mutations against integrase inhibitors | E-poster | Resistance to ART |